Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Saved in:
| Title: | Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study. |
|---|---|
| Authors: | Overton, Edgar T1 edgar.t.overton@viivhealthcare.com, Richmond, Gary2, Rizzardini, Giuliano3,4, Thalme, Anders5, Girard, Pierre-Marie6, Wong, Alexander7, Porteiro, Norma8, Swindells, Susan9, Reynes, Jacques10,11, Noe, Sebastian12, Harrington, Conn13, Español, Carlos Martín14, Acuipil, Carolina15, Aksar, Asma16, Wang, Yuanyuan17, Ford, Susan L18, Crauwels, Herta19, Eygen, Veerle van20, Solingen-Ristea, Rodica Van21, Latham, Christine L22 |
| Source: | Clinical Infectious Diseases. May2023, Vol. 76 Issue 9, p1646-1654. 9p. |
| Database: | Environment Complete |
Be the first to leave a comment!
